BERLIN — The leading professional organization for European oncologists has rolled out its first set of guidance on how its members should use large language models, a type of artificial intelligence, in cancer medicine.
“The oncology community cannot ignore the potential benefits which AI technology can provide to cancer patients,” the authors of the guidance wrote, while simultaneously acknowledging that there aren’t enough evaluations of the chatbots available to patients or tools available to doctors to address the risks associated with generative AI in medicine.
The guidance’s release — it was published last Saturday in the Annals of Oncology — coincided with the annual meeting for the European Society of Clinical Oncology in Berlin. The American Society of Clinical Oncology has issued its own set of principles for the responsible use of AI in cancer medicine, but has not released recommendations specific to LLMs.
This article is exclusive to STAT+ subscribers
Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
